NCT06352528 2025-10-06
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
Bristol-Myers Squibb
Phase 1 Completed
Clinical Trials
5 trialsNCT06425198 2025-01-22
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
Bristol-Myers Squibb
Phase 1 Completed
NCT04639115 2022-06-14
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
Celgene
Phase 1 Completed
NCT01273155 2019-03-26
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02717949 2019-01-08
Optimal
University of Texas Southwestern Medical Center
Phase 4 Terminated